Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- New trial
Multiple solid tumors
Phase 1/2a VBC101: EGFR and cMET targeted bispecific antibody drug conjugate
This multicenter, open-label, multiple-dose first-in-human trial by VelaVigo Bio Inc evaluates VBC101 using an accelerated titration in Phase 1 dose escalation with a BOIN design and backfill cohorts to define the…
NCT07136779 First-in-human - New trial
Multiple solid tumors
Phase 1/2 TER-2013 (undisclosed target) trial in AKT/PI3K/PTEN-altered solid tumors
This open-label, multicenter study evaluates safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of lysine covalently binding small molecule TER-2013 (that may attack TRIP13…
NCT07109726 Exploratory - Trial result Spotlight
Non-small cell lung cancer
CT-P16 (bevacizumab biosimilar, anti-VEGF) matches reference bevacizumab in nsNSCLC
From a South Korean biopharma company, Celltrion’s CT-P16 is a bevacizumab biosimilar (anti-VEGF-A mAb). In a randomized, double-blind, global, multicenter Phase 3 first-line study for metastatic/recurrent…
NCT03676192 - Trial result Spotlight
Pancreatic cancer
Atorvastatin (HMG-CoA) + chemotherapy shows 70.3% tumor-marker declines in advanced PDAC
Atorvastatin, an HMG-CoA reductase inhibitor (statin), was paired with chemotherapy after a 260-line PDAC organoid biobank tied chemoresistance to cholesterol/glycosylation programs and showed statins could…
NCT06241352 - Trial result Spotlight
Pancreatic cancer
ELI-002 2P (mKRAS amphiphile) links strong T-cell response to longer RFS/OS in PDAC/CRC
ELI-002 2P is a lymph-node–targeted amphiphile vaccine (KRAS G12D/G12R peptides + CpG-7909) tested as monotherapy in MRD-positive patients after locoregional therapy in Phase 1 AMPLIFY-201 (n=25; PDAC=20, CRC=5). At…
- Trial result Spotlight
Brain and CNS tumors
Azeliragon (RAGE) + SRS posts 100% 8-wk per-patient RANO response in brain metastases
Azeliragon is an oral, brain-penetrant inhibitor of the receptor for advanced glycation end-products (RAGE) intended to dampen neuroinflammation/edema and potentially radiosensitize tumors; in the single-center Phase…
NCT05789589 - Trial result
Melanoma
Melphalan ILP (regional alkylator): CD8+ phenotype predicts CR in in-transit melanoma
Melphalan-based isolated limb perfusion (ILP) delivers high-dose regional alkylating chemotherapy; this single-center retrospective study (Sweden) tested whether baseline peripheral-blood immunophenotype predicts…
NCT03685890 - Trial result
Lymphoma
Ultrasensitive ctDNA-MRD outperforms PET for defining remission in frontline LBCL
Led by NCI in collaboration with Stanford (developers of PhasED-Seq) and Foresight Diagnostics (CLARITY MRD assay), ultrasensitive ctDNA minimal residual disease (MRD) testing using phased-variant detection (e.g.,…
NCT04002947 - New trial Spotlight
Breast cancer
Phase 3 patritumab deruxtecan study of HER3-directed ADC in HR+/HER2- breast cancer
This open-label, randomized Phase 3 trial, sponsored by Merck Sharp & Dohme LLC, evaluates whether patritumab deruxtecan—a HER3-directed antibody–drug conjugate delivering a topoisomerase I inhibitor—improves…
NCT07060807 Registrational - New trial
Breast cancer
Pilot SBIR trial: MBI-guided biopsy using radiotracer uptake to target tumor metabolism.
This pilot trial by Smart Breast Corp. compares supplemental molecular breast imaging (MBI) to standard digital breast tomosynthesis (DBT) for cancer detection in women with dense breasts (BIRADS C or D).…
NCT07114679 Exploratory - New trial
Breast cancer
Phase 1 Pilot Study of Breast Radiation: Ionizing DNA Damage Agent
This multi-institutional pilot study led by Alexander Stessin explores whether adding whole-breast external beam radiation therapy to standard care can reduce cancer progression in patients with unresectable, locally…
NCT07122713 Exploratory - New trial Spotlight
Multiple myeloma
Phase 3 Belantamab Mafodotin Trial – BCMA-targeting ADC in Transplant-Ineligible Myeloma
This Phase 3 randomized, open-label trial at GlaxoSmithKline compares belantamab mafodotin (a BCMA-directed antibody-drug conjugate with a tubulin inhibitor payload) plus lenalidomide and dexamethasone versus…
NCT06679101 Registrational - New trial
Multiple myeloma
Phase 1/2 mRNA-2808 mRNA gene therapy vaccine for relapsed/refractory multiple myeloma
This open-label, multicenter study led by ModernaTX assesses the safety and tolerability of mRNA-2808, an mRNA vaccine using an undisclosed antigen, in adults with relapsed or refractory multiple myeloma.…
NCT07116616 First-in-human - New trial Spotlight
Brain and CNS tumors
Phase 1 CART-EGFR-IL13Rα2 Cells Targeting EGFR and IL13Rα2 in GBM
This open-label study at the University of Pennsylvania examines newly diagnosed glioblastoma patients with EGFR-amplification and MGMT-unmethylation post-radiotherapy. Eligible patients undergo a two-step screening,…
NCT06973096 First-in-human - New trial Spotlight
Pancreatic cancer
Phase 1b Study of ASP2138, a CLDN18.2-directed CD3 Activator Bispecific mAb
Adults with resectable pancreatic ductal adenocarcinoma expressing CLDN18.2 receive neoadjuvant subcutaneous ASP2138 followed by investigator-selected adjuvant chemotherapy (mFOLFIRINOX, gemcitabine/nab-paclitaxel,…
NCT07024615 Exploratory - New trial
Kidney cancer
Phase 2 Sasanlimab PD-1 mAb trial for advanced renal cell carcinoma
This Phase 2 trial evaluates the safety and efficacy of a combination regimen in advanced clear cell or translocation renal cell carcinoma. Participants receive sasanlimab (a PD-1-targeted monoclonal antibody),…
NCT07123090 Exploratory - New trial
Prostate cancer
Phase 1b study: JNJ-78278343 KLK2/CD3 bispecific and JNJ-95298177 PSMA ADC for prostate cancer.
This study by Janssen Research & Development evaluates combined dose finding and expansion using a Bayesian Optimal Interval design. It investigates JNJ-78278343, a T-cell redirecting KLK2/CD3 bispecific antibody,…
NCT07082920 Exploratory - New trial
Prostate cancer
Phase 2 ASP5541 Abiraterone Decanoate CYP17 Inhibitor in Advanced Prostate Cancer
This open-label multi-cohort trial by Astellas Pharma Global Development evaluates ASP5541, an intramuscular form of abiraterone decanoate (a CYP17 inhibitor), versus standard oral abiraterone acetate with…
NCT07005154 Exploratory - New trial Spotlight
Small cell lung cancer
Phase 3 trial of tarlatamab, a DLL3/CD3 bispecific antibody, in extensive-stage SCLC.
This Phase 3 open-label, multicenter randomized trial compares tarlatamab plus durvalumab, carboplatin, and etoposide versus standard durvalumab, carboplatin, and etoposide in untreated stage IV extensive-stage…
NCT07005128 Registrational - New trial
Head and neck cancer
Phase II trial of Carboplatin, a platinum-based DNA synthesis inhibitor, in oral cancer.
This study evaluates personalized treatment for resectable oral squamous cell carcinoma using sentinel lymph node mapping combined with targeted radiation and chemotherapy. Interventions include carboplatin…
NCT07121595 Exploratory - New trial
Lymphoma
Phase II trial: Epcoritamab bispecific antibody (CD20/CD3) plus EPOCH-R in aggressive B-cell NHL.
University of Washington is conducting a Phase II study to evaluate the safety, tolerability, and efficacy of epcoritamab—with its CD20/CD3 targeting mechanism—combined with standard EPOCH-R chemotherapy. The study…
NCT07097363 Exploratory - New trial
Lymphoma
Phase 1 trial of TLN-121, a talin-1 targeted integrin β1 adhesion inhibitor
This open-label, multicenter study sponsored by Treeline Biosciences, Inc. evaluates the safety, pharmacokinetics, and preliminary anti-tumor activity of TLN-121 alone or combined with TLN-254, a BCL6 degrader small…
NCT07082803 First-in-human - New trial
Lymphoma
Phase I/II trial of AZD4512, a CD22‐directed antibody-drug conjugate.
This global open-label study evaluates the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of AZD4512 administered as monotherapy dose escalation (with backfill cohorts) or in combination…
NCT07123454 First-in-human - New trial
Sarcoma and GIST
Phase 2 Pembrolizumab PD-1 Inhibitor Study in Ultra-Rare Sarcomas
This minibasket study by Memorial Sloan Kettering assesses whether pembrolizumab—a PD-1 inhibitor that releases immune brakes—is safe and effective in ultra-rare sarcomas (including pleomorphic liposarcoma,…
NCT07089992 Exploratory - New trial Spotlight
Stomach and esophageal cancer
Phase 3 Zolbetuximab (CLDN18.2 mAb) trial in advanced gastric/GEJ cancer
This study compares zolbetuximab combined with pembrolizumab and chemotherapy versus placebo in adults with unresectable or metastatic stomach or GEJ adenocarcinoma that are HER2-negative, CLDN18.2-positive, and…
NCT06901531 Registrational - New trial Spotlight
Multiple solid tumors
Phase 1/2 OBI-902 TROP-2 antibody-drug conjugate trial in advanced solid tumors
This trial is designed to evaluate the safety, pharmacokinetics, and clinical activity of OBI-902 as dose-finding monotherapy in a phase 1 setting and at an optimized dose in phase 2 expansion cohorts. It includes…
NCT07124117 First-in-human - New trial
Multiple solid tumors
Phase 1 Trial of CYTALUX™ (Pafolacianine) Folate Receptor-Targeted Intraoperative Imaging Agent.
This Phase 1 open-label trial by Cedars-Sinai Medical Center is evaluating the feasibility of using CYTALUX™ (pafolacianine), a folate receptor directed fluorescent imaging agent, in adults with gastric, esophageal,…
NCT07124351 Exploratory - New trial
Multiple solid tumors
Phase 1 Trial of XB371 Topoisomerase Inhibitor
This trial evaluates first-in-human TF–topoisomerase-I inhibitor ADC (XB371), in participants with locally advanced or metastatic solid tumors. Using dose-escalation cohorts and randomized expansion parts A and B,…
NCT07123103 First-in-human - New trial
Multiple solid tumors
Phase 1a/b study of LY4257496, a GRPR-targeted beta emitter radioligand
This two-part, open-label trial evaluates safety, tolerability, and preliminary efficacy of LY4257496 administered alone or with standard-of-care agents—including fulvestrant, imlunestrant, aromatase inhibitor,…
NCT07114601 First-in-human - New trial Spotlight
Multiple solid tumors
Phase I/II Trial of AZD6750, CD8-guided IL-2 fusion protein, in advanced solid tumors
This trial evaluates the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of AZD6750 as a single agent or in combination with rilvegostomig—a Tigit and PD-1 bispecific mAb—in adult participants…
NCT07115043 First-in-human
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.